Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
LogicBio Therapeutics reports Q1 EPS (41c), consensus (48c) » 17:34
05/11/20
05/11
17:34
05/11/20
17:34
LOGC

LogicBio Therapeutics

$6.60 /

-0.77 (-10.45%)

Reports Q1 revenue $1.02M…

Reports Q1 revenue $1.02M vs. $0 last year. The company said, "LogicBio has been actively monitoring the COVID-19 pandemic and its impact globally. LogicBio's objectives have remained the same throughout the pandemic: to support the safety of its team members and their families and continue its research and development activities to develop genetic medicines that have the potential to durably treat rare diseases in pediatric patients with significant unmet medical need. Since mid-March, the Company's non-laboratory employees have been working remotely to comply with social distancing and "stay at home" orders as well as applicable guidelines from the U.S. Centers for Disease Control and Prevention. LogicBio's laboratory employees, whose work must be performed on premises, have been working in shifts to continue in-house research and manufacturing activities on a decreased basis. LogicBio has also ceased all business travel for its employees and plans to maintain these or similar restrictions on its business activities until LogicBio believes that its employees can fully resume such activities in accordance with federal, state and local requirements and guidelines."

ShowHide Related Items >><<
LOGC LogicBio Therapeutics
$6.60 /

-0.77 (-10.45%)

01/10/20 Roth Capital
LogicBio reported 'two wins' with updates, says Roth Capital
Over a quarter ago
Hot Stocks
LogicBio Therapeutics provides update on IND for trial of MMA patients » 16:18
03/16/20
03/16
16:18
03/16/20
16:18
LOGC

LogicBio Therapeutics

$4.06 /

-0.44 (-9.78%)

In January, the company…

In January, the company announced the submission of an IND to support the initiation of a Phase 1/2 clinical trial in pediatric patients with MMA, which the FDA placed on clinical hold. Subsequently, we received a letter from the FDA specifying its questions related to the clinical hold. The clinical hold was based on questions that were clinical and nonclinical in nature, including questions related to the studies conducted for our IND filing, but did not relate to chemistry, manufacturing, and controls. The company expects to have interactions with the FDA regarding their questions through mid-2020, after which we plan to provide guidance on the anticipated timing for the initiation of the Phase 1/2 clinical trial for LB-001. Cash, cash equivalents and investments were $50.6M as of December 31, 2019. Based upon the current operating plan, which takes into account expenditures that are contingent based on corporate developments, the company believes that cash and cash equivalents and short-term investments as of December 31, 2019 will enable the company to fund operating expenses and capital expenditure requirements into Q1 of 2021.

ShowHide Related Items >><<
LOGC LogicBio Therapeutics
$4.06 /

-0.44 (-9.78%)

01/10/20 Roth Capital
LogicBio reported 'two wins' with updates, says Roth Capital
05/01/19 Roth Capital
LogicBio Therapeutics initiated with a Buy at Roth Capital
Hot Stocks
Fly Intel: After Hours Movers » 18:41
02/10/20
02/10
18:41
02/10/20
18:41
AMKR

Amkor Technology

$11.56 /

+0.49 (+4.43%)

, FLDM

Fluidigm

$3.67 /

-0.12 (-3.17%)

, OMF

OneMain Holdings

$44.95 /

+1.2 (+2.74%)

, RNG

RingCentral

$212.58 /

+5.58 (+2.70%)

, XPO

XPO Logistics

$94.19 /

+1.115 (+1.20%)

, BHF

Brighthouse Financial

$42.06 /

-0.15 (-0.36%)

, STE

Steris

$153.92 /

+1.01 (+0.66%)

, S

Sprint

$4.80 /

-0.135 (-2.74%)

, TMUS

T-Mobile

$84.56 /

-0.94 (-1.10%)

, OII

Oceaneering

$12.54 /

-0.305 (-2.37%)

, AVRO

Avrobio

$26.20 /

+2.36 (+9.90%)

, GNSS

Genasys

$3.74 /

+0.01 (+0.27%)

, ELY

Callaway Golf

$20.56 /

+0.36 (+1.78%)

, APPS

Digital Turbine

$6.47 /

+0.465 (+7.74%)

, RLGT

Radiant Logistics

$5.06 /

+ (+0.00%)

, RPD

Rapid7

$62.36 /

+2.02 (+3.35%)

, CHGG

Chegg

$44.57 /

+1.84 (+4.31%)

, MELI

MercadoLibre

$657.76 /

+13 (+2.02%)

, BRX

Brixmor

$21.35 /

+0.48 (+2.30%)

, MIME

Mimecast

$53.52 /

+0.625 (+1.18%)

, AIN

Albany International

$72.12 /

+0.2 (+0.28%)

, MOH

Molina Healthcare

$129.23 /

+1.17 (+0.91%)

, VRNS

Varonis

$92.18 /

+2.27 (+2.52%)

, IIVI

II-VI

$35.34 /

+0.35 (+1.00%)

, KMPR

Kemper

$81.01 /

+0.94 (+1.17%)

, LOGC

LogicBio Therapeutics

$10.40 /

-0.58 (-5.28%)

, XERS

Xeris Pharmaceuticals

$6.05 /

-0.05 (-0.82%)

, RVNC

Revance

$26.92 /

+0.31 (+1.16%)

, TBPH

Theravance Biopharma

$30.60 /

+ (+0.00%)

, ADVM

Adverum Biotechnologies

$12.05 /

+1.805 (+17.63%)

UP AFTER EARNINGS: Amkor…

UP AFTER EARNINGS: Amkor (AMKR) up 16.7%... Fluidigm (FLDM) up 13.2%... OneMain Holdings (OMF) up 3.8%... RingCentral (RNG) up 3.4%... XPO Logistics (XPO) up 2.6%... Brighthouse Financial (BHF) up 2.0%... Steris (STE) up 2.0%. ALSO HIGHER: Spring (S) up 54.0%, T-Mobile (TMUS) up 7.7% after getting judge's approval to complete merger... Oceaneering (OII) up 3.8% after getting light well intervention contract from BP... Avrobio (AVRO) up 2.2% after positive initial data on its Cystinosis program. DOWN AFTER EARNINGS: Genasys (GNSS) down 7.7%... Callaway Golf (ELY) down 6.6%... Digital Turbine (APPS) down 6.4%... Radiant Logistics (RLGT) down 6.3%... Rapid7 (RPD) down 5.4%... Chegg (CHGG) down 4.3%... MercadoLibre (MELI) down 3.9%... Brixmor Property (BRX) down 3.8%... Mimecast (MIME) down 3.7%... Albany International (AIN) down 3.0%... Molina Healthcare (MOH) down 2.6%... Varonis (VRNS) down 2.4%... II-VI (IIVI) down 1.7%... Kemper (KMPR) down 1.4%. ALSO LOWER: LogicBio (LOGC) down 26.3% after FDA placed clinical hold on submission of LB-001... Xeris Pharma (XERS) down 7.5% after equity offering... Revance Therapeutics (RVNC) down 5.3% after convertible debt offering... Theravance Biopharma (TBPH) down 5.2% after equity offering... Adverum Biotech (ADVM) down 3.7% after equity offering. Movers as of 18:30ET.

ShowHide Related Items >><<
AMKR Amkor Technology
$11.56 /

+0.49 (+4.43%)

10/29/19
Fly Intel: Top five analyst upgrades
10/29/19 Deutsche Bank
Amkor Technology price target raised to $12 from $8 at Deutsche Bank
10/29/19 Credit Suisse
Amkor Technology upgraded to Outperform from Neutral at Credit Suisse
FLDM Fluidigm
$3.67 /

-0.12 (-3.17%)

01/14/20 Piper Sandler
Piper Sandler reiterates Overweight on Fluidigm after Q4 results, guidance
11/06/19 Janney Montgomery Scott
Fluidigm downgraded to Neutral after Q3 miss at Janney Montgomery Scott
11/06/19 Janney Montgomery Scott
Fluidigm downgraded to Neutral from Buy at Janney Montgomery Scott
10/18/19 UBS
Fluidigm upgraded to Buy from Neutral at UBS
OMF OneMain Holdings
$44.95 /

+1.2 (+2.74%)

01/07/20 Citi
Citi makes changes to 'Value Creators' SMID Focus List
01/06/20 Keefe Bruyette
OneMain credit performance to benefit from wage hikes, says Keefe Bruyette
12/27/19 Stephens
Fiserv, SurveyMonkey among stocks dropped from Stephens Best Ideas list
11/21/19 Stephens
OneMain Holdings reiterated as top pick after investor day at Stephens
RNG RingCentral
$212.58 /

+5.58 (+2.70%)

02/04/20 SunTrust
RingCentral price target raised to $225 from $192 at SunTrust
01/27/20 Wells Fargo
RingCentral initiated with an Overweight at Wells Fargo
01/27/20 Wells Fargo
RingCentral initiated with an Overweight at Wells Fargo
01/23/20 Needham
RingCentral price target raised to $220 from $190 at Needham
XPO XPO Logistics
$94.19 /

+1.115 (+1.20%)

01/27/20
Fly Intel: Top five analyst downgrades
01/27/20 Barclays
XPO Logistics downgraded to Equal Weight from Overweight at Barclays
01/16/20 Cowen
XPO Logistics price target raised to $125 from $100 at Cowen
01/16/20 Cowen
XPO Logistics price target raised to $125 from $100 at Cowen
BHF Brighthouse Financial
$42.06 /

-0.15 (-0.36%)

01/08/20 Goldman Sachs
Brighthouse Financial upgraded to Neutral from Sell at Goldman Sachs
01/06/20 Wells Fargo
Brighthouse Financial downgraded to Underweight at Wells Fargo
01/06/20 Wells Fargo
Brighthouse downgraded to Underweight from Equal Weight at Wells Fargo
01/03/20 Credit Suisse
Brighthouse Financial upgraded at Credit Suisse on capital developments
STE Steris
$153.92 /

+1.01 (+0.66%)

07/10/19 KeyBanc
Steris downgraded to Sector Weight on valuation at KeyBanc
07/09/19 KeyBanc
STERIS downgraded to Sector Weight from Overweight at KeyBanc
05/15/19 Stephens
STERIS price target raised to $150 from $135 at Stephens
S Sprint
$4.80 /

-0.135 (-2.74%)

02/07/20 SunTrust
T-Mobile price target raised to $100 from $95 at SunTrust
01/28/20 Cowen
Sprint outsized risk on no deal remains, says Cowen
01/10/20 KeyBanc
American Tower price target raised to $254 from $242 at KeyBanc
01/07/20 Nomura Instinet
T-Mobile upgraded to Buy from Neutral at Nomura Instinet
TMUS T-Mobile
$84.56 /

-0.94 (-1.10%)

01/06/20 Cowen
T-Mobile should be bought on any Sprint deal denial, says Cowen
OII Oceaneering
$12.54 /

-0.305 (-2.37%)

01/13/20 Bernstein
Oceaneering initiated with an Underperform at Bernstein
12/17/19 Goldman Sachs
Oceaneering upgraded to Buy from Neutral at Goldman Sachs
12/12/19 Evercore ISI
Oceaneering upgraded to Outperform from In Line at Evercore ISI
11/21/19 Wolfe Research
Oceaneering initiated with an Outperform at Wolfe Research
AVRO Avrobio
$26.20 /

+2.36 (+9.90%)

06/27/19 Mizuho
Mizuho starts Avrobio with Buy rating, $28 price target
06/26/19 Mizuho
Avrobio initiated with a Buy at Mizuho
04/05/19 Janney Montgomery Scott
Avrobio initiated with a Buy at Janney Montgomery Scott
GNSS Genasys
$3.74 /

+0.01 (+0.27%)

ELY Callaway Golf
$20.56 /

+0.36 (+1.78%)

02/05/20 Compass Point
USGA 'distance report' presents threat to Callaway, Acushnet, says Compass Point
01/29/20 Imperial Capital
Callaway Golf price target raised to $26 from $22 at Imperial Capital
01/06/20 Jefferies
Jefferies downgrades Acushnet to Hold on valuation, prefers Callaway
01/02/20 Stephens
Stephens releases Best Ideas list for 2020
APPS Digital Turbine
$6.47 /

+0.465 (+7.74%)

12/17/19 National Securities
Digital Turbine reinstated with a Buy at National Securities
06/27/19 Canaccord
Digital Turbine initiated with a Buy at Canaccord
06/19/19 B. Riley FBR
Digital Turbine price target raised to $6 from $5 at B. Riley FBR
06/04/19 Ladenburg
Digital Turbine price target raised to $5.10 from $4.50 at Ladenburg
RLGT Radiant Logistics
$5.06 /

+ (+0.00%)

02/12/19 Loop Capital
Loop Capital sees as Radiant Logistics 'attractive growth opportunity'
RPD Rapid7
$62.36 /

+2.02 (+3.35%)

01/22/20 Raymond James
Rapid7 price target raised to $75 from $69 at Raymond James
12/10/19 Piper Sandler
Rapid7 initiated with an Overweight, $67 target at Piper Jaffray
12/09/19 Piper Sandler
Rapid7 initiated with an Overweight at Piper Jaffray
12/03/19 RBC Capital
Rapid7 can deliver sustainable, above-market growth, says RBC Capital
CHGG Chegg
$44.57 /

+1.84 (+4.31%)

01/29/20 Northland
Amazon seems to be getting more aggressive in textbooks, says Northland
01/21/20 Citi
Chegg price target raised to $50 from $38.50 at Citi
11/25/19 Morgan Stanley
Chegg resumed with an Overweight at Morgan Stanley
11/05/19 Citi
Chegg upgraded to Buy after better than expected guidance at Citi
MELI MercadoLibre
$657.76 /

+13 (+2.02%)

02/07/20 Credit Suisse
MercadoLibre price target raised to $750 from $680 at Credit Suisse
02/06/20 Jefferies
MercadoLibre initiated with a Hold at Jefferies
02/05/20 Susquehanna
MercadoLibre upgraded to Positive at Susquehanna
02/05/20 Susquehanna
MercadoLibre upgraded to Positive from Neutral at Susquehanna
BRX Brixmor
$21.35 /

+0.48 (+2.30%)

01/16/20 SunTrust
Brixmor downgraded to Hold from Buy at SunTrust
01/15/20 SunTrust
Brixmor downgraded to Hold from Buy at SunTrust
01/15/20 Jefferies
Brixmor initiated with a Hold at Jefferies
01/07/20 BMO Capital
Brixmor downgraded to Underperform from Market Perform at BMO Capital
MIME Mimecast
$53.52 /

+0.625 (+1.18%)

01/13/20 Monness Crespi
Mimecast price target raised to $58 ahead of investor day at Monness Crespi
11/08/19
Mimecast downgraded to Neutral from Buy at Dougherty
08/21/19 Rosenblatt
Mimecast initiated with a Buy at Rosenblatt
08/13/19 BofA
Crowdstrike price target raised to $103 from $89 at BofA/Merrill
AIN Albany International
$72.12 /

+0.2 (+0.28%)

01/13/20 JPMorgan
Albany International initiated with a Neutral at JPMorgan
10/22/19 Baird
Albany International downgraded to Neutral at Baird
10/22/19 Baird
Albany International downgraded to Neutral from Outperform at Baird
09/12/19 BofA
Albany International initiated with a Buy at BofA/Merrill
MOH Molina Healthcare
$129.23 /

+1.17 (+0.91%)

01/07/20 Deutsche Bank
Molina Healthcare price target raised to $150 from $145 at Deutsche Bank
12/24/19 Stephens
Kentucky Medicaid rebidding news a disappointment for Molina, says Stephens
12/20/19 JPMorgan
JPMorgan reverses stance on Managed Care, turns more bullish into 2020
12/19/19 JPMorgan
ACA ruling removes partial overhang on Centene and Molina, says JPMorgan
VRNS Varonis
$92.18 /

+2.27 (+2.52%)

01/13/20 Morgan Stanley
Varonis upgraded to Overweight on subscription benefits at Morgan Stanley
01/13/20 Morgan Stanley
Varonis upgraded to Overweight from Equal Weight at Morgan Stanley
01/06/20 Benchmark
Benchmark names Alibaba, Nvidia, Comcast among best ideas for first half
10/29/19 Craig-Hallum
Varonis price target raised to $82 from $75 at Craig-Hallum
IIVI II-VI
$35.34 /

+0.35 (+1.00%)

01/10/20 Raymond James
II-VI downgraded to Market Perform on valuation at Raymond James
01/10/20 Raymond James
II-VI downgraded to Market Perform from Outperform at Raymond James
01/02/20 Needham
II-VI price target raised to $43 from $40 at Needham
12/18/19 Canaccord
II-VI initiated with a Buy at Canaccord
KMPR Kemper
$81.01 /

+0.94 (+1.17%)

09/09/19 UBS
Kemper initiated with a Buy at UBS
08/23/19 William Blair
William Blair cuts Kemper to Market Perform, sees earnings momentum slowing
08/22/19 William Blair
Kemper downgraded to Market Perform from Outperform at William Blair
03/01/19 William Blair
William Blair more confident in top 2019 pick Kemper after Q4 results
LOGC LogicBio Therapeutics
$10.40 /

-0.58 (-5.28%)

01/10/20 Roth Capital
LogicBio reported 'two wins' with updates, says Roth Capital
05/01/19 Roth Capital
LogicBio Therapeutics initiated with a Buy at Roth Capital
XERS Xeris Pharmaceuticals
$6.05 /

-0.05 (-0.82%)

09/11/19 Mizuho
Xeris Pharmaceuticals price target lowered to $22 from $27 at Mizuho
06/07/19 Mizuho
Xeris selloff on PDUFA extension a buying opportunity, says Mizuho
RVNC Revance
$26.92 /

+0.31 (+1.16%)

01/23/20 Mizuho
Revance price target raised to $39 from $34 at Mizuho
01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
01/10/20 William Blair
Revance deal positions it as 'emerging aesthetics leader,' says William Blair
12/01/19 Goldman Sachs
Revance initiated with a Buy at Goldman Sachs
TBPH Theravance Biopharma
$30.60 /

+ (+0.00%)

01/08/20 H.C. Wainwright
Theravance Biopharma price target raised to $30 from $25 at H.C. Wainwright
11/21/19 Cantor Fitzgerald
Cantor calls Theravance shares 'undervalued and underappreciated'
11/06/19 Baird
Theravance Biopharma upgraded to Neutral at Baird
11/06/19 Baird
Theravance Biopharma upgraded to Neutral from Underperform at Baird
ADVM Adverum Biotechnologies
$12.05 /

+1.805 (+17.63%)

02/10/20 Chardan
Chardan upgraded Adverum to Buy after data, doubles price target to $20
02/10/20 Chardan
Adverum Biotechnologies upgraded to Buy from Neutral at Chardan
02/09/20 Cantor Fitzgerald
Adverum Biotechnologies upgraded to Overweight from Neutral at Cantor Fitzgerald
02/09/20 Piper Sandler
Adverum '022 shaping up to be potentially superior treatment, says Piper Sandler
  • 12
    Feb
  • 12
    Feb
  • 12
    Feb
Hot Stocks
LogicBio Therapeutics down 26% after FDA update for LB-001 » 18:20
02/10/20
02/10
18:20
02/10/20
18:20
LOGC

LogicBio Therapeutics

$10.40 /

-0.58 (-5.28%)

Shares of LogicBio…

Shares of LogicBio Therapeutics are down 26.3% at $7.70 after the company announced that the FDA has "placed a clinical hold on the Investigational New Drug submission for LB-001 for the treatment of methylmalonic acidemia pending the resolution of certain clinical and nonclinical questions. The Company submitted the IND in January 2020 to support the initiation of a Phase 1/2 clinical trial in patients with MMA. LogicBio expects that the FDA questions will be provided in writing within 30 days. LogicBio plans to work closely with the FDA to resolve these questions as quickly as possible. "

ShowHide Related Items >><<
LOGC LogicBio Therapeutics
$10.40 /

-0.58 (-5.28%)

01/10/20 Roth Capital
LogicBio reported 'two wins' with updates, says Roth Capital
05/01/19 Roth Capital
LogicBio Therapeutics initiated with a Buy at Roth Capital
Hot Stocks
LogicBio Therapeutics Inc trading resumes  16:35
02/10/20
02/10
16:35
02/10/20
16:35
LOGC

LogicBio Therapeutics

$10.40 /

-0.58 (-5.28%)

 
ShowHide Related Items >><<
LOGC LogicBio Therapeutics
$10.40 /

-0.58 (-5.28%)

01/10/20 Roth Capital
LogicBio reported 'two wins' with updates, says Roth Capital
05/01/19 Roth Capital
LogicBio Therapeutics initiated with a Buy at Roth Capital
Hot Stocks
LogicBio Therapeutics Inc trading halted, news pending  16:00
02/10/20
02/10
16:00
02/10/20
16:00
LOGC

LogicBio Therapeutics

$10.32 /

-0.665 (-6.06%)

 
ShowHide Related Items >><<
LOGC LogicBio Therapeutics
$10.32 /

-0.665 (-6.06%)

01/10/20 Roth Capital
LogicBio reported 'two wins' with updates, says Roth Capital
05/01/19 Roth Capital
LogicBio Therapeutics initiated with a Buy at Roth Capital
Recommendations
LogicBio reported 'two wins' with updates, says Roth Capital » 13:11
01/10/20
01/10
13:11
01/10/20
13:11
LOGC

LogicBio Therapeutics

$7.24 /

+0.21 (+2.99%)

Roth Capital analyst…

Roth Capital analyst Yasmeen Rahimi called LogicBio Therapeutics' IND submission to initiate a Phase 1/2 trial of LB-001 and its announcement of a research collaboration with Takeda Pharmaceutical (TAK) for a second GeneRide indication "two wins to start the new year right." She views Takeda's decision to fund LB-301 development for the treatment of Crigler-Najjar syndrome as strong validation of the GeneRide platform and thinks this may only be the start of partnership news given that that two other liver indications have showed therapeutic effects from GeneRide preclinically. Rahimi has a Buy rating and $26 price target on LogicBio shares.

ShowHide Related Items >><<
LOGC LogicBio Therapeutics
$7.24 /

+0.21 (+2.99%)

05/01/19 Roth Capital
LogicBio Therapeutics initiated with a Buy at Roth Capital
Hot Stocks
LogicBio Therapeutics to move into new headquarters in spring 2020 » 07:36
01/10/20
01/10
07:36
01/10/20
07:36
LOGC

LogicBio Therapeutics

$7.03 /

+0.2 (+2.93%)

The company said,…

The company said, "Doubling available lab and office space to support GeneRide platform development and capabilities expansion. LogicBio expects to move into new headquarters in Lexington, Mass. in the spring of 2020. LogicBio will be adding vivarium space, internal development capabilities, and will increase its capacity for in-house manufacturing of preclinical material. The expanded lab space will support the continued advancement of a robust pipeline that builds on the modular GeneRide construct. The new facilities will also support continued growth of the capsid program, which aims to develop and license new state-of-the-art viral vectors."

ShowHide Related Items >><<
LOGC LogicBio Therapeutics
$7.03 /

+0.2 (+2.93%)

05/01/19 Roth Capital
LogicBio Therapeutics initiated with a Buy at Roth Capital
Hot Stocks
LogicBio to present additional findings from AAV capsid candidates in 2020 » 07:35
01/10/20
01/10
07:35
01/10/20
07:35
LOGC

LogicBio Therapeutics

$7.03 /

+0.2 (+2.93%)

The company said,…

The company said, "Reported positive data on Next Generation Capsid Development program at European Society of Gene and Cell Therapy Annual Meeting. Data were presented from a set of novel, synthetic adeno-associated virus capsid candidates tested against references AAV2, AAV8, and LK-03. All capsids showed selective tropism and more potent transduction and gene expression than the reference capsids in human hepatocytes of a chimeric FRG mouse model. LogicBio, working in partnership with the Children's Medical Research Institute, intends to advance this research and present additional findings at a scientific conference in 2020."

ShowHide Related Items >><<
LOGC LogicBio Therapeutics
$7.03 /

+0.2 (+2.93%)

05/01/19 Roth Capital
LogicBio Therapeutics initiated with a Buy at Roth Capital
Hot Stocks
LogicBio, Takeda announce collaboration to develop LB-301 » 07:08
01/10/20
01/10
07:08
01/10/20
07:08
LOGC

LogicBio Therapeutics

$7.03 /

+0.2 (+2.93%)

, TAK

Takeda Pharmaceutical

$19.79 /

+0.16 (+0.82%)

LogicBio Therapeutics…

LogicBio Therapeutics (LOGC) announced a research collaboration with Takeda Pharmaceutical Company Limited (TAK) to further develop LB-301, an investigational therapy using LogicBio's proprietary, promoterless, nuclease-free genome editing technology, GeneRide, for the treatment of Crigler-Najjar syndrome. LB-301 is a recombinant adeno-associated viral (AAV) vector with a uridine disphosphate-glucuronosyltransferase-1 gene. The collaboration will bring together LogicBio's propriety platform for genome editing and Takeda's expertise in researching and developing gene therapies. Under the agreement, LogicBio and Takeda will collaborate to further research and develop LB-301. Takeda will provide funding for the research program under the collaboration agreement and will have an exclusive option to negotiate an exclusive, worldwide license to LogicBio's LB-301 program.

ShowHide Related Items >><<
LOGC LogicBio Therapeutics
$7.03 /

+0.2 (+2.93%)

05/01/19 Roth Capital
LogicBio Therapeutics initiated with a Buy at Roth Capital
TAK Takeda Pharmaceutical
$19.79 /

+0.16 (+0.82%)

11/19/19 Needham
Phathom Pharmaceuticals initiated with a Buy at Needham
11/01/19 Cowen
Takeda Pharmaceutical initiated with a Market Perform at Cowen
09/24/19 Jefferies
Takeda Pharmaceutical initiated with a Buy at Jefferies
09/05/19 H.C. Wainwright
H.C. Wainwright says KemPharm may have picked 'best possible' partner in GPC

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.